NCT01262638

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 177 (actual)
• Sponsor: Esperion Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	ETC-1002	ETC-1002 daily for 12 weeks
DRUG	Placebo	Placebo daily for 12 weeks

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-08-23
• Completion: 2011-08-23
• First posted: 2010-12-17
• Last updated: 2021-03-17
• Results posted: 2021-03-16

Locations

11 sites across 1 country: United States